Histamine in cancer immunology and immunotherapy. Current status and new perspectives.

Pharmacol Res Perspect · 2021 · PMC8491460 · PMID 34609067

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

230 Post hoc analyses of efficacy in morphological subtypes of AML among patients participating in the HDC/IL‐2 phase III trial, showed a nonsignificant trend toward improvement of LFS in those patients with M0/M1 (undifferentiated/minimal maturation) AML versus controls.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.